Statera Biopharma Stock Number Of Employees
Statera Biopharma fundamentals help investors to digest information that contributes to Statera Biopharma's financial success or failures. It also enables traders to predict the movement of Statera Pink Sheet. The fundamental analysis module provides a way to measure Statera Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Statera Biopharma pink sheet.
Statera |
Statera Biopharma Company Number Of Employees Analysis
Statera Biopharma's Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Current Statera Biopharma Number Of Employees | 46 |
Most of Statera Biopharma's fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Statera Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
CompetitionBased on the recorded statements, Statera Biopharma is currently employing 46.0 people. This is 99.58% lower than that of the Healthcare sector and 91.41% lower than that of the Biotechnology industry. The number of employees for all United States stocks is 99.76% higher than that of the company.
Statera Number Of Employees Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Statera Biopharma's direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Statera Biopharma could also be used in its relative valuation, which is a method of valuing Statera Biopharma by comparing valuation metrics of similar companies.Statera Biopharma is currently under evaluation in number of employees category among its peers.
Statera Fundamentals
| Return On Equity | -2.87 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (5.73) % | ||||
| Current Valuation | 12.92 M | ||||
| Shares Outstanding | 54.66 M | ||||
| Shares Owned By Insiders | 15.93 % | ||||
| Shares Owned By Institutions | 5.41 % | ||||
| Number Of Shares Shorted | 1.25 M | ||||
| Price To Book | 0.16 X | ||||
| Price To Sales | 1.61 X | ||||
| Revenue | 1.49 M | ||||
| Gross Profit | 998.72 K | ||||
| EBITDA | (97.27 M) | ||||
| Net Income | (101.88 M) | ||||
| Cash And Equivalents | 506.1 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 10.62 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (28.19 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Number Of Employees | 46 | ||||
| Market Capitalization | 1.97 M | ||||
| Total Asset | 21.17 M | ||||
| Z Score | -13.2 | ||||
| Net Asset | 21.17 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |